Latest News





07-30-15 Zogenix Prices Public Offering of Common Stock
07-28-15 Zogenix Announces Proposed Public Offering of 3,800,000 Shares of Common Stock
07-07-15 Zogenix to Host Key Opinion Leader Meeting Tuesday, July 14, in New York City

  Relday is a proprietary, once-monthly subcutaneous formulation of risperidone for treating schizophrenia. The Relday Multi-Dose study was initiated in January and results are anticipated in Q3 2015.

  DosePro is a first-in-class, easy-to-use drug delivery system designed for self-administration of a pre-filled, single dose of liquid drug, subcutaneously, without a needle. DosePro offers benefits to patients including instant, easy dosing, less anxiety over self-injection, no need for sharps disposal, no risk of needle stick injury or contamination, and reliable performance.